Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Подходы к изучению влияния кишечной микробиоты на развитие метаболических нарушений
Подходы к изучению влияния кишечной микробиоты на развитие метаболических нарушений
Шестакова Е.А., Покровская Е.В., Самсонова М.Д. Подходы к изучению влияния кишечной микробиоты на развитие метаболических нарушений. Consilium Medicum. 2021;23(12):905–909.
DOI: 10.26442/20751753.2021.12.201289
DOI: 10.26442/20751753.2021.12.201289
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Ожирение и сахарный диабет 2-го типа (СД 2) – две неинфекционные пандемии XXI в. Несмотря на большое количество исследований, посвященных причинам развития ожирения и СД 2, преодолеть неуклонный рост числа заболевших не удается. В этих условиях необходим поиск новых подходов к профилактике и лечению нарушений углеводного обмена. Одним из таких подходов является изучение механизмов воздействия кишечной микробиоты на развитие нарушений углеводного и липидного обмена. Данный обзор посвящен исследованиям, описывающим роль микробиоты в формировании ожирения и нарушений углеводного обмена. Цель обзора – описать различные подходы к изменению состава кишечной микробиоты и определить их влияние на метаболические риски. Для оценки роли изменения состава микробиоты в развитии ожирения и СД 2 нами рассмотрен ряд исследований, посвященных хронологии возникновения этих процессов в различных ситуациях. В обзор включены исследования по оценке влияния на состав микробиоты медикаментозного лечения, бариатрических оперативных вмешательств, а также трансплантации кишечной микробиоты. Также представлены данные о возможном метаболически протективном составе кишечной микробиоты.
Ключевые слова: ожирение, сахарный диабет 2-го типа, кишечная микробиота, трансплантация кишечной микробиоты, антибиотики, ингибиторы протонной помпы, бариатрическая хирургия
Keywords: obesity, diabetes mellitus type 2, gut microbiota, fecal microbiota transplantation, antibiotics, proton pump inhibitors, bariatric surgery
Ключевые слова: ожирение, сахарный диабет 2-го типа, кишечная микробиота, трансплантация кишечной микробиоты, антибиотики, ингибиторы протонной помпы, бариатрическая хирургия
________________________________________________
Keywords: obesity, diabetes mellitus type 2, gut microbiota, fecal microbiota transplantation, antibiotics, proton pump inhibitors, bariatric surgery
Полный текст
Список литературы
1. Шестакова Е.А., Лунина Е.Ю., Галстян Г.Р., и др. Распространенность нарушений углеводного обмена у лиц с различными сочетаниями факторов риска сахарного диабета 2 типа в когорте пациентов исследования NATION. Сахарный диабет. 2020;23(1):4-11 [Shestakova EA, Lunina EY, Galstyan GR, et al. Type 2 diabetes and prediabetes preavalance in patients with different risk factor combinations in THE NATION study. Diabetes Mellitus. 2020;23(1):4-11 (in Russian)].
DOI:10.14341/DM12286
2. Hills RD Jr, Pontefract BA, Mishcon HR, et al. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 2019;11(7):1613. DOI:10.3390/nu11071613
3. Mohajeri MH, Brummer RJM, Rastall RA, et al. The role of the microbiome for human health: from basic science to clinical applications. Eur J Nutr. 2018;57(Suppl. 1):1-14. DOI:10.1007/s00394-018-1703-4
4. Singh RK, Chang HW, Yan D, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017;15(1):73. DOI:10.1186/s12967-017-1175-y
5. Кравчук Е.Н., Неймарк А.Е., Гринева Е.Н., и др. Регуляция метаболических процессов, опосредованная кишечной микрофлорой. Сахарный диабет. 2016;19(4):280-5 [Kravchuk EN, Neimark AE, Grineva EN, et al. The role of gut microbiota in metabolic regulation. Diabetes Mellitus. 2016;19(4):280-5 (in Russian)].
6. Демидова Т.Ю., Лобанова К.Г., Ойноткинова О.Ш. Кишечная микробиота как фактор риска развития ожирения и сахарного диабета 2-го типа. Терапевтический архив. 2020;92(10):97-104 [Demidova TY, Lobanova KG, Oinotkinova OS. Gut microbiota is a factor of risk for obesity and type 2 diabetes. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(10):97-104 (in Russian)]. DOI:10.26442/00403660.2020.10.000778
7. Barko PC, McMichael MA, Swanson KS, et al. The Gastrointestinal Microbiome: A Review. J Vet Intern Med. 2018;32(1):9-25. DOI:10.1111/jvim.14875
8. Janda JM, Abbott SL. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. J Clin Microbiol. 2007;45(9):2761-4. DOI:10.1128/JCM.01228-07
9. Lee YY, Hassan SA, Ismail IH, et al. Gut microbiota in early life and its influence on health and disease: A position paper by the Malaysian Working Group on Gastrointestinal Health. J Paediatr Child Health. 2017;53(12):1152-8. DOI:10.1111/jpc.13640
10. Mangiola F, Nicoletti A, Gasbarrini A, Ponziani FR. Gut microbiota and aging. Eur Rev Med Pharmacol Sci. 2018;22(21):7404-13. DOI:10.26355/eurrev_201811_16280
11. Shoaie S, Ghaffari P, Kovatcheva-Datchary P, et al. Quantifying Diet-Induced Metabolic Changes of the Human Gut Microbiome. Cell Metab. 2015;22(2):320-31. DOI:10.1016/j.cmet.2015.07.001
12. Wu L, Zeng T, Zinellu A, et al. A Cross-Sectional Study of Compositional and Functional Profiles of Gut Microbiota in Sardinian Centenarians. mSystems. 2019;4(4):e00325-19. DOI:10.1128/mSystems.00325-19
13. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016;8(1):39. DOI:10.1186/s13073-016-0294-z
14. Partap U, Allcock SH, Parker E, et al. Association between early life antibiotic use and childhood overweight and obesity: a narrative review. Glob Health Epidemiol Genom. 2018;3:e18. DOI:10.1017/gheg.2018.16
15. Mikkelsen KH, Allin KH, Knop FK. Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature. Diabetes Obes Metab. 2016;18(5):444-53. DOI:10.1111/dom.12637
16. Leong KSW, McLay J, Derraik JGB, et al. Associations of Prenatal and Childhood Antibiotic Exposure With Obesity at Age 4 Years. JAMA Netw Open. 2020;3(1):e1919681. DOI:10.1001/jamanetworkopen.2019.19681
17. Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutr Clin Pract. 2018;33(5):614-24. DOI:10.1002/ncp.10181
18. Hafiz RA, Wong C, Paynter S, et al. The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis. Ann Pharmacother. 2018;52(7):613-22. DOI:10.1177/1060028018760569
19. Yuan J, He Q, Nguyen LH, et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut. 2020;70(6):1070-7. DOI:10.1136/gutjnl-2020-322557
20. Pareek M, Schauer PR, Kaplan LM, et al. Metabolic Surgery: Weight Loss, Diabetes, and Beyond. J Am Coll Cardiol. 2018;71(6):670-87. DOI:10.1016/j.jacc.2017.12.014
21. Wolfe BM, Kvach E, Eckel RH. Treatment of Obesity: Weight Loss and Bariatric Surgery. Circ Res. 2016;118(11):1844-55. DOI:10.1161/CIRCRESAHA.116.307591
22. Ciobârcă D, Cătoi AF, Copăescu C, et al. Bariatric Surgery in Obesity: Effects on Gut Microbiota and Micronutrient Status. Nutrients. 2020;12(1):235. DOI:10.3390/nu12010235
23. Celiker H. A new proposed mechanism of action for gastric bypass surgery: Air hypothesis. Med Hypotheses. 2017;107:81-9. DOI:10.1016/j.mehy.2017.08.012
24. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341(6150):1241214. DOI:10.1126/science.1241214
25. Proença IM, Allegretti JR, Bernardo WM, et al. Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. Nutr Res. 2020;83:1-14. DOI:10.1016/j.nutres.2020.06.018
26. Mocanu V, Zhang Z, Deehan EC, et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nat Med. 2021;27:1272-9. DOI:10.1038/s41591-021-01399-2
27. Allegretti JR, Kassam Z, Hurtado J, et al. Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. Hormones (Athens). 2021;20(1):209-11. DOI:10.1007/s42000-020-00265-z
28. Yu EW, Gao L, Stastka P, et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med. 2020;17(3):e1003051. DOI:10.1371/journal.pmed.1003051
29. Allegretti JR, Kassam Z, Mullish BH, at al. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clin Gastroenterol Hepatol. 2020;18(4):855-63.e2. DOI:10.1016/j.cgh.2019.07.006
30. Kim B, Choi HN, Yim JE. Effect of Diet on the Gut Microbiota Associated with Obesity. J Obes Metab Syndr. 2019;28(4):216-24. DOI:10.7570/jomes.2019.28.4.216
31. Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:1025907. DOI:10.1016/j.ebiom.2019.11.051
32. Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014;38(5):996-1047.
DOI:10.1111/1574-6976.12075
33. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65. DOI:10.1038/nature08821
34. Leylabadlo HE, Sanaie S, Heravi FS, et al. From role of gut microbiota to microbial-based therapies in type 2-diabetes. Infect Genet Evol. 2020;81:104268. DOI:10.1016/j.meegid.2020.104268
35. Sikalidis AK, Maykish A. The Gut Microbiome and Type 2 Diabetes Mellitus: Discussing a Complex Relationship. Biomedicines. 2020;8(1):8. DOI:10.3390/biomedicines8010008
36. Egshatyan L, Kashtanova D, Popenko A, et al. Gut microbiota and diet in patients with different glucose tolerance. Endocr Connect. 2016;5(1):1-9. DOI:10.1530/EC-15-0094
37. Hjorth MF, Christensen L, Kjølbæk L, et al. Pretreatment Prevotella-to-Bacteroides ratio and markers of glucose metabolism as prognostic markers for dietary weight loss maintenance. Eur J Clin Nutr. 2020;74(2):338-47. DOI:10.1038/s41430-019-0466-1
38. Roager HM, Licht TR, Poulsen SK, et al. Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet. Appl Environ Microbiol. 2014;80(3):1142-9. DOI:10.1128/AEM.03549-13
39. Halawa MR, El-Salam MA, Mostafa BM, Sallout SS. The Gut Microbiome, Lactobacillus acidophilus; Relation with Type 2 Diabetes Mellitus. Curr Diabetes Rev. 2019;15(6):480-5. DOI:10.2174/1573399815666190206162143
40. Ferrarese R, Ceresola ER, Preti A, Canducci F. Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era. Eur Rev Med Pharmacol Sci. 2018;22(21):7588-605. DOI:10.26355/eurrev_201811_16301
41. Gomes JMG, Costa JA, Alfenas RCG. Metabolic endotoxemia and diabetes mellitus: A systematic review. Metabolism. 2017;68:133-44. DOI:10.1016/j.metabol.2016.12.009
2. Hills RD Jr, Pontefract BA, Mishcon HR, et al. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 2019;11(7):1613. DOI:10.3390/nu11071613
3. Mohajeri MH, Brummer RJM, Rastall RA, et al. The role of the microbiome for human health: from basic science to clinical applications. Eur J Nutr. 2018;57(Suppl. 1):1-14. DOI:10.1007/s00394-018-1703-4
4. Singh RK, Chang HW, Yan D, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017;15(1):73. DOI:10.1186/s12967-017-1175-y
5. Kravchuk EN, Neimark AE, Grineva EN, et al. The role of gut microbiota in metabolic regulation. Diabetes Mellitus. 2016;19(4):280-5 (in Russian).
6. Demidova TY, Lobanova KG, Oinotkinova OS. Gut microbiota is a factor of risk for obesity and type 2 diabetes. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(10):97-104 (in Russian). DOI:10.26442/00403660.2020.10.000778
7. Barko PC, McMichael MA, Swanson KS, et al. The Gastrointestinal Microbiome: A Review. J Vet Intern Med. 2018;32(1):9-25. DOI:10.1111/jvim.14875
8. Janda JM, Abbott SL. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. J Clin Microbiol. 2007;45(9):2761-4. DOI:10.1128/JCM.01228-07
9. Lee YY, Hassan SA, Ismail IH, et al. Gut microbiota in early life and its influence on health and disease: A position paper by the Malaysian Working Group on Gastrointestinal Health. J Paediatr Child Health. 2017;53(12):1152-8. DOI:10.1111/jpc.13640
10. Mangiola F, Nicoletti A, Gasbarrini A, Ponziani FR. Gut microbiota and aging. Eur Rev Med Pharmacol Sci. 2018;22(21):7404-13. DOI:10.26355/eurrev_201811_16280
11. Shoaie S, Ghaffari P, Kovatcheva-Datchary P, et al. Quantifying Diet-Induced Metabolic Changes of the Human Gut Microbiome. Cell Metab. 2015;22(2):320-31. DOI:10.1016/j.cmet.2015.07.001
12. Wu L, Zeng T, Zinellu A, et al. A Cross-Sectional Study of Compositional and Functional Profiles of Gut Microbiota in Sardinian Centenarians. mSystems. 2019;4(4):e00325-19. DOI:10.1128/mSystems.00325-19
13. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016;8(1):39. DOI:10.1186/s13073-016-0294-z
14. Partap U, Allcock SH, Parker E, et al. Association between early life antibiotic use and childhood overweight and obesity: a narrative review. Glob Health Epidemiol Genom. 2018;3:e18. DOI:10.1017/gheg.2018.16
15. Mikkelsen KH, Allin KH, Knop FK. Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature. Diabetes Obes Metab. 2016;18(5):444-53. DOI:10.1111/dom.12637
16. Leong KSW, McLay J, Derraik JGB, et al. Associations of Prenatal and Childhood Antibiotic Exposure With Obesity at Age 4 Years. JAMA Netw Open. 2020;3(1):e1919681. DOI:10.1001/jamanetworkopen.2019.19681
17. Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutr Clin Pract. 2018;33(5):614-24. DOI:10.1002/ncp.10181
18. Hafiz RA, Wong C, Paynter S, et al. The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis. Ann Pharmacother. 2018;52(7):613-22. DOI:10.1177/1060028018760569
19. Yuan J, He Q, Nguyen LH, et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut. 2020;70(6):1070-7. DOI:10.1136/gutjnl-2020-322557
20. Pareek M, Schauer PR, Kaplan LM, et al. Metabolic Surgery: Weight Loss, Diabetes, and Beyond. J Am Coll Cardiol. 2018;71(6):670-87. DOI:10.1016/j.jacc.2017.12.014
21. Wolfe BM, Kvach E, Eckel RH. Treatment of Obesity: Weight Loss and Bariatric Surgery. Circ Res. 2016;118(11):1844-55. DOI:10.1161/CIRCRESAHA.116.307591
22. Ciobârcă D, Cătoi AF, Copăescu C, et al. Bariatric Surgery in Obesity: Effects on Gut Microbiota and Micronutrient Status. Nutrients. 2020;12(1):235. DOI:10.3390/nu12010235
23. Celiker H. A new proposed mechanism of action for gastric bypass surgery: Air hypothesis. Med Hypotheses. 2017;107:81-9. DOI:10.1016/j.mehy.2017.08.012
24. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341(6150):1241214. DOI:10.1126/science.1241214
25. Proença IM, Allegretti JR, Bernardo WM, et al. Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. Nutr Res. 2020;83:1-14. DOI:10.1016/j.nutres.2020.06.018
26. Mocanu V, Zhang Z, Deehan EC, et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nat Med. 2021;27:1272-9. DOI:10.1038/s41591-021-01399-2
27. Allegretti JR, Kassam Z, Hurtado J, et al. Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. Hormones (Athens). 2021;20(1):209-11. DOI:10.1007/s42000-020-00265-z
28. Yu EW, Gao L, Stastka P, et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med. 2020;17(3):e1003051. DOI:10.1371/journal.pmed.1003051
29. Allegretti JR, Kassam Z, Mullish BH, at al. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clin Gastroenterol Hepatol. 2020;18(4):855-63.e2. DOI:10.1016/j.cgh.2019.07.006
30. Kim B, Choi HN, Yim JE. Effect of Diet on the Gut Microbiota Associated with Obesity. J Obes Metab Syndr. 2019;28(4):216-24. DOI:10.7570/jomes.2019.28.4.216
31. Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:1025907. DOI:10.1016/j.ebiom.2019.11.051
32. Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014;38(5):996-1047.
DOI:10.1111/1574-6976.12075
33. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65. DOI:10.1038/nature08821
34. Leylabadlo HE, Sanaie S, Heravi FS, et al. From role of gut microbiota to microbial-based therapies in type 2-diabetes. Infect Genet Evol. 2020;81:104268. DOI:10.1016/j.meegid.2020.104268
35. Sikalidis AK, Maykish A. The Gut Microbiome and Type 2 Diabetes Mellitus: Discussing a Complex Relationship. Biomedicines. 2020;8(1):8. DOI:10.3390/biomedicines8010008
36. Egshatyan L, Kashtanova D, Popenko A, et al. Gut microbiota and diet in patients with different glucose tolerance. Endocr Connect. 2016;5(1):1-9. DOI:10.1530/EC-15-0094
37. Hjorth MF, Christensen L, Kjølbæk L, et al. Pretreatment Prevotella-to-Bacteroides ratio and markers of glucose metabolism as prognostic markers for dietary weight loss maintenance. Eur J Clin Nutr. 2020;74(2):338-47. DOI:10.1038/s41430-019-0466-1
38. Roager HM, Licht TR, Poulsen SK, et al. Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet. Appl Environ Microbiol. 2014;80(3):1142-9. DOI:10.1128/AEM.03549-13
39. Halawa MR, El-Salam MA, Mostafa BM, Sallout SS. The Gut Microbiome, Lactobacillus acidophilus; Relation with Type 2 Diabetes Mellitus. Curr Diabetes Rev. 2019;15(6):480-5. DOI:10.2174/1573399815666190206162143
40. Ferrarese R, Ceresola ER, Preti A, Canducci F. Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era. Eur Rev Med Pharmacol Sci. 2018;22(21):7588-605. DOI:10.26355/eurrev_201811_16301
41. Gomes JMG, Costa JA, Alfenas RCG. Metabolic endotoxemia and diabetes mellitus: A systematic review. Metabolism. 2017;68:133-44. DOI:10.1016/j.metabol.2016.12.009
DOI:10.14341/DM12286
2. Hills RD Jr, Pontefract BA, Mishcon HR, et al. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 2019;11(7):1613. DOI:10.3390/nu11071613
3. Mohajeri MH, Brummer RJM, Rastall RA, et al. The role of the microbiome for human health: from basic science to clinical applications. Eur J Nutr. 2018;57(Suppl. 1):1-14. DOI:10.1007/s00394-018-1703-4
4. Singh RK, Chang HW, Yan D, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017;15(1):73. DOI:10.1186/s12967-017-1175-y
5. Кравчук Е.Н., Неймарк А.Е., Гринева Е.Н., и др. Регуляция метаболических процессов, опосредованная кишечной микрофлорой. Сахарный диабет. 2016;19(4):280-5 [Kravchuk EN, Neimark AE, Grineva EN, et al. The role of gut microbiota in metabolic regulation. Diabetes Mellitus. 2016;19(4):280-5 (in Russian)].
6. Демидова Т.Ю., Лобанова К.Г., Ойноткинова О.Ш. Кишечная микробиота как фактор риска развития ожирения и сахарного диабета 2-го типа. Терапевтический архив. 2020;92(10):97-104 [Demidova TY, Lobanova KG, Oinotkinova OS. Gut microbiota is a factor of risk for obesity and type 2 diabetes. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(10):97-104 (in Russian)]. DOI:10.26442/00403660.2020.10.000778
7. Barko PC, McMichael MA, Swanson KS, et al. The Gastrointestinal Microbiome: A Review. J Vet Intern Med. 2018;32(1):9-25. DOI:10.1111/jvim.14875
8. Janda JM, Abbott SL. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. J Clin Microbiol. 2007;45(9):2761-4. DOI:10.1128/JCM.01228-07
9. Lee YY, Hassan SA, Ismail IH, et al. Gut microbiota in early life and its influence on health and disease: A position paper by the Malaysian Working Group on Gastrointestinal Health. J Paediatr Child Health. 2017;53(12):1152-8. DOI:10.1111/jpc.13640
10. Mangiola F, Nicoletti A, Gasbarrini A, Ponziani FR. Gut microbiota and aging. Eur Rev Med Pharmacol Sci. 2018;22(21):7404-13. DOI:10.26355/eurrev_201811_16280
11. Shoaie S, Ghaffari P, Kovatcheva-Datchary P, et al. Quantifying Diet-Induced Metabolic Changes of the Human Gut Microbiome. Cell Metab. 2015;22(2):320-31. DOI:10.1016/j.cmet.2015.07.001
12. Wu L, Zeng T, Zinellu A, et al. A Cross-Sectional Study of Compositional and Functional Profiles of Gut Microbiota in Sardinian Centenarians. mSystems. 2019;4(4):e00325-19. DOI:10.1128/mSystems.00325-19
13. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016;8(1):39. DOI:10.1186/s13073-016-0294-z
14. Partap U, Allcock SH, Parker E, et al. Association between early life antibiotic use and childhood overweight and obesity: a narrative review. Glob Health Epidemiol Genom. 2018;3:e18. DOI:10.1017/gheg.2018.16
15. Mikkelsen KH, Allin KH, Knop FK. Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature. Diabetes Obes Metab. 2016;18(5):444-53. DOI:10.1111/dom.12637
16. Leong KSW, McLay J, Derraik JGB, et al. Associations of Prenatal and Childhood Antibiotic Exposure With Obesity at Age 4 Years. JAMA Netw Open. 2020;3(1):e1919681. DOI:10.1001/jamanetworkopen.2019.19681
17. Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutr Clin Pract. 2018;33(5):614-24. DOI:10.1002/ncp.10181
18. Hafiz RA, Wong C, Paynter S, et al. The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis. Ann Pharmacother. 2018;52(7):613-22. DOI:10.1177/1060028018760569
19. Yuan J, He Q, Nguyen LH, et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut. 2020;70(6):1070-7. DOI:10.1136/gutjnl-2020-322557
20. Pareek M, Schauer PR, Kaplan LM, et al. Metabolic Surgery: Weight Loss, Diabetes, and Beyond. J Am Coll Cardiol. 2018;71(6):670-87. DOI:10.1016/j.jacc.2017.12.014
21. Wolfe BM, Kvach E, Eckel RH. Treatment of Obesity: Weight Loss and Bariatric Surgery. Circ Res. 2016;118(11):1844-55. DOI:10.1161/CIRCRESAHA.116.307591
22. Ciobârcă D, Cătoi AF, Copăescu C, et al. Bariatric Surgery in Obesity: Effects on Gut Microbiota and Micronutrient Status. Nutrients. 2020;12(1):235. DOI:10.3390/nu12010235
23. Celiker H. A new proposed mechanism of action for gastric bypass surgery: Air hypothesis. Med Hypotheses. 2017;107:81-9. DOI:10.1016/j.mehy.2017.08.012
24. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341(6150):1241214. DOI:10.1126/science.1241214
25. Proença IM, Allegretti JR, Bernardo WM, et al. Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. Nutr Res. 2020;83:1-14. DOI:10.1016/j.nutres.2020.06.018
26. Mocanu V, Zhang Z, Deehan EC, et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nat Med. 2021;27:1272-9. DOI:10.1038/s41591-021-01399-2
27. Allegretti JR, Kassam Z, Hurtado J, et al. Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. Hormones (Athens). 2021;20(1):209-11. DOI:10.1007/s42000-020-00265-z
28. Yu EW, Gao L, Stastka P, et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med. 2020;17(3):e1003051. DOI:10.1371/journal.pmed.1003051
29. Allegretti JR, Kassam Z, Mullish BH, at al. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clin Gastroenterol Hepatol. 2020;18(4):855-63.e2. DOI:10.1016/j.cgh.2019.07.006
30. Kim B, Choi HN, Yim JE. Effect of Diet on the Gut Microbiota Associated with Obesity. J Obes Metab Syndr. 2019;28(4):216-24. DOI:10.7570/jomes.2019.28.4.216
31. Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:1025907. DOI:10.1016/j.ebiom.2019.11.051
32. Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014;38(5):996-1047.
DOI:10.1111/1574-6976.12075
33. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65. DOI:10.1038/nature08821
34. Leylabadlo HE, Sanaie S, Heravi FS, et al. From role of gut microbiota to microbial-based therapies in type 2-diabetes. Infect Genet Evol. 2020;81:104268. DOI:10.1016/j.meegid.2020.104268
35. Sikalidis AK, Maykish A. The Gut Microbiome and Type 2 Diabetes Mellitus: Discussing a Complex Relationship. Biomedicines. 2020;8(1):8. DOI:10.3390/biomedicines8010008
36. Egshatyan L, Kashtanova D, Popenko A, et al. Gut microbiota and diet in patients with different glucose tolerance. Endocr Connect. 2016;5(1):1-9. DOI:10.1530/EC-15-0094
37. Hjorth MF, Christensen L, Kjølbæk L, et al. Pretreatment Prevotella-to-Bacteroides ratio and markers of glucose metabolism as prognostic markers for dietary weight loss maintenance. Eur J Clin Nutr. 2020;74(2):338-47. DOI:10.1038/s41430-019-0466-1
38. Roager HM, Licht TR, Poulsen SK, et al. Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet. Appl Environ Microbiol. 2014;80(3):1142-9. DOI:10.1128/AEM.03549-13
39. Halawa MR, El-Salam MA, Mostafa BM, Sallout SS. The Gut Microbiome, Lactobacillus acidophilus; Relation with Type 2 Diabetes Mellitus. Curr Diabetes Rev. 2019;15(6):480-5. DOI:10.2174/1573399815666190206162143
40. Ferrarese R, Ceresola ER, Preti A, Canducci F. Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era. Eur Rev Med Pharmacol Sci. 2018;22(21):7588-605. DOI:10.26355/eurrev_201811_16301
41. Gomes JMG, Costa JA, Alfenas RCG. Metabolic endotoxemia and diabetes mellitus: A systematic review. Metabolism. 2017;68:133-44. DOI:10.1016/j.metabol.2016.12.009
________________________________________________
2. Hills RD Jr, Pontefract BA, Mishcon HR, et al. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 2019;11(7):1613. DOI:10.3390/nu11071613
3. Mohajeri MH, Brummer RJM, Rastall RA, et al. The role of the microbiome for human health: from basic science to clinical applications. Eur J Nutr. 2018;57(Suppl. 1):1-14. DOI:10.1007/s00394-018-1703-4
4. Singh RK, Chang HW, Yan D, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017;15(1):73. DOI:10.1186/s12967-017-1175-y
5. Kravchuk EN, Neimark AE, Grineva EN, et al. The role of gut microbiota in metabolic regulation. Diabetes Mellitus. 2016;19(4):280-5 (in Russian).
6. Demidova TY, Lobanova KG, Oinotkinova OS. Gut microbiota is a factor of risk for obesity and type 2 diabetes. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(10):97-104 (in Russian). DOI:10.26442/00403660.2020.10.000778
7. Barko PC, McMichael MA, Swanson KS, et al. The Gastrointestinal Microbiome: A Review. J Vet Intern Med. 2018;32(1):9-25. DOI:10.1111/jvim.14875
8. Janda JM, Abbott SL. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. J Clin Microbiol. 2007;45(9):2761-4. DOI:10.1128/JCM.01228-07
9. Lee YY, Hassan SA, Ismail IH, et al. Gut microbiota in early life and its influence on health and disease: A position paper by the Malaysian Working Group on Gastrointestinal Health. J Paediatr Child Health. 2017;53(12):1152-8. DOI:10.1111/jpc.13640
10. Mangiola F, Nicoletti A, Gasbarrini A, Ponziani FR. Gut microbiota and aging. Eur Rev Med Pharmacol Sci. 2018;22(21):7404-13. DOI:10.26355/eurrev_201811_16280
11. Shoaie S, Ghaffari P, Kovatcheva-Datchary P, et al. Quantifying Diet-Induced Metabolic Changes of the Human Gut Microbiome. Cell Metab. 2015;22(2):320-31. DOI:10.1016/j.cmet.2015.07.001
12. Wu L, Zeng T, Zinellu A, et al. A Cross-Sectional Study of Compositional and Functional Profiles of Gut Microbiota in Sardinian Centenarians. mSystems. 2019;4(4):e00325-19. DOI:10.1128/mSystems.00325-19
13. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016;8(1):39. DOI:10.1186/s13073-016-0294-z
14. Partap U, Allcock SH, Parker E, et al. Association between early life antibiotic use and childhood overweight and obesity: a narrative review. Glob Health Epidemiol Genom. 2018;3:e18. DOI:10.1017/gheg.2018.16
15. Mikkelsen KH, Allin KH, Knop FK. Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature. Diabetes Obes Metab. 2016;18(5):444-53. DOI:10.1111/dom.12637
16. Leong KSW, McLay J, Derraik JGB, et al. Associations of Prenatal and Childhood Antibiotic Exposure With Obesity at Age 4 Years. JAMA Netw Open. 2020;3(1):e1919681. DOI:10.1001/jamanetworkopen.2019.19681
17. Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutr Clin Pract. 2018;33(5):614-24. DOI:10.1002/ncp.10181
18. Hafiz RA, Wong C, Paynter S, et al. The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis. Ann Pharmacother. 2018;52(7):613-22. DOI:10.1177/1060028018760569
19. Yuan J, He Q, Nguyen LH, et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut. 2020;70(6):1070-7. DOI:10.1136/gutjnl-2020-322557
20. Pareek M, Schauer PR, Kaplan LM, et al. Metabolic Surgery: Weight Loss, Diabetes, and Beyond. J Am Coll Cardiol. 2018;71(6):670-87. DOI:10.1016/j.jacc.2017.12.014
21. Wolfe BM, Kvach E, Eckel RH. Treatment of Obesity: Weight Loss and Bariatric Surgery. Circ Res. 2016;118(11):1844-55. DOI:10.1161/CIRCRESAHA.116.307591
22. Ciobârcă D, Cătoi AF, Copăescu C, et al. Bariatric Surgery in Obesity: Effects on Gut Microbiota and Micronutrient Status. Nutrients. 2020;12(1):235. DOI:10.3390/nu12010235
23. Celiker H. A new proposed mechanism of action for gastric bypass surgery: Air hypothesis. Med Hypotheses. 2017;107:81-9. DOI:10.1016/j.mehy.2017.08.012
24. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341(6150):1241214. DOI:10.1126/science.1241214
25. Proença IM, Allegretti JR, Bernardo WM, et al. Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. Nutr Res. 2020;83:1-14. DOI:10.1016/j.nutres.2020.06.018
26. Mocanu V, Zhang Z, Deehan EC, et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nat Med. 2021;27:1272-9. DOI:10.1038/s41591-021-01399-2
27. Allegretti JR, Kassam Z, Hurtado J, et al. Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. Hormones (Athens). 2021;20(1):209-11. DOI:10.1007/s42000-020-00265-z
28. Yu EW, Gao L, Stastka P, et al. Fecal microbiota transplantation for the improvement of metabolism in obesity: The FMT-TRIM double-blind placebo-controlled pilot trial. PLoS Med. 2020;17(3):e1003051. DOI:10.1371/journal.pmed.1003051
29. Allegretti JR, Kassam Z, Mullish BH, at al. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clin Gastroenterol Hepatol. 2020;18(4):855-63.e2. DOI:10.1016/j.cgh.2019.07.006
30. Kim B, Choi HN, Yim JE. Effect of Diet on the Gut Microbiota Associated with Obesity. J Obes Metab Syndr. 2019;28(4):216-24. DOI:10.7570/jomes.2019.28.4.216
31. Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:1025907. DOI:10.1016/j.ebiom.2019.11.051
32. Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev. 2014;38(5):996-1047.
DOI:10.1111/1574-6976.12075
33. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65. DOI:10.1038/nature08821
34. Leylabadlo HE, Sanaie S, Heravi FS, et al. From role of gut microbiota to microbial-based therapies in type 2-diabetes. Infect Genet Evol. 2020;81:104268. DOI:10.1016/j.meegid.2020.104268
35. Sikalidis AK, Maykish A. The Gut Microbiome and Type 2 Diabetes Mellitus: Discussing a Complex Relationship. Biomedicines. 2020;8(1):8. DOI:10.3390/biomedicines8010008
36. Egshatyan L, Kashtanova D, Popenko A, et al. Gut microbiota and diet in patients with different glucose tolerance. Endocr Connect. 2016;5(1):1-9. DOI:10.1530/EC-15-0094
37. Hjorth MF, Christensen L, Kjølbæk L, et al. Pretreatment Prevotella-to-Bacteroides ratio and markers of glucose metabolism as prognostic markers for dietary weight loss maintenance. Eur J Clin Nutr. 2020;74(2):338-47. DOI:10.1038/s41430-019-0466-1
38. Roager HM, Licht TR, Poulsen SK, et al. Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet. Appl Environ Microbiol. 2014;80(3):1142-9. DOI:10.1128/AEM.03549-13
39. Halawa MR, El-Salam MA, Mostafa BM, Sallout SS. The Gut Microbiome, Lactobacillus acidophilus; Relation with Type 2 Diabetes Mellitus. Curr Diabetes Rev. 2019;15(6):480-5. DOI:10.2174/1573399815666190206162143
40. Ferrarese R, Ceresola ER, Preti A, Canducci F. Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era. Eur Rev Med Pharmacol Sci. 2018;22(21):7588-605. DOI:10.26355/eurrev_201811_16301
41. Gomes JMG, Costa JA, Alfenas RCG. Metabolic endotoxemia and diabetes mellitus: A systematic review. Metabolism. 2017;68:133-44. DOI:10.1016/j.metabol.2016.12.009
Авторы
Е.А. Шестакова*1, Е.В. Покровская1, М.Д. Самсонова2
1 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия;
2 ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова», Москва, Россия
*katiashestakova@mail.ru
1 Endocrinology Research Centre, Moscow, Russia;
2 Lomonosov Moscow State University, Moscow, Russia
*katiashestakova@mail.ru
1 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия;
2 ФГБОУ ВО «Московский государственный университет им. М.В. Ломоносова», Москва, Россия
*katiashestakova@mail.ru
________________________________________________
1 Endocrinology Research Centre, Moscow, Russia;
2 Lomonosov Moscow State University, Moscow, Russia
*katiashestakova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.